Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …

Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased
destruction of autologous erythrocytes by autoantibodies with or without complement …

Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that
selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the …

The article presents guidelines for the diagnosis and management of patients with primary
autoimmune haemolytic anaemia (AIHA). Topics discussed include diagnostic approach to …

The clinical outcome, response to treatment, and occurrence of acute complications were
retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and …

Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by
autoantibodies directed against self red blood cells. It can be idiopathic or secondary, and …

Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients
with autoimmune hemolytic anemia. We reviewed the clinical and pathologic features …

We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5
countries. In Norway and a northern region of Italy, the study was close to being population …

Autoimmune hemolytic anemias mediated by cold agglutinins can be divided into cold
agglutinin disease (CAD), which is a well-defined clinicopathologic entity and a clonal …

Autoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic,
prognostic, and therapeutic dilemmas despite being a well-recognized entity for over 150 …